---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Cost-effectiveness evidence"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Cost-effectiveness evidence. Topics: Summary: absence of vonaprument economic evaluations and comparator cost-effectiveness evidence, Manufacturer statement on payer assessment of cost-effectiveness, Pegcetacoplan cost-effectiveness analysis: U.S. Medicare costs and cost per QALY, Avacincaptad pegol cost-effectiveness analysis: comparison with pegcetacoplan, and 4 further topics. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics/cost-effectiveness"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Cost-effectiveness evidence

<a id="heading-4.1"></a>

## 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

### Summary: absence of vonaprument economic evaluations and comparator cost-effectiveness evidence

No cost-effectiveness analysis, budget impact model, health technology assessment, or price of vonaprument (ANX007) was identified. ARCHER II, the phase 3 trial of monthly vonaprument 5.0 mg per eye versus sham in 659 participants, had a Data Monitoring Committee assessment of its Month 15 primary endpoint scheduled for the fourth quarter of 2026, so no product-specific efficacy input for a model was available. The manufacturer states that there is no assurance a product will be considered “cost-effective by third-party payors”. The comparator evidence consists of analyses of the two complement inhibitors approved in the United States, pegcetacoplan and avacincaptad pegol.

Two U.S. cost analyses based on 2022 Medicare reimbursement, estimated 2-year treatment costs of $70,000 (every month) and $34,600 (every other month) for pegcetacoplan, with modeled costs per QALY gained of $706,000 and $397,000, and 2-year costs of $67,400 (every month) and $40,600 (every other month) for avacincaptad pegol. For extrafoveal GA, the cost per mm2 of retinal pigment epithelium saved was higher with avacincaptad pegol than with pegcetacoplan for both dosing regimens ($119,000 vs $54,000 every month; $57,100 vs $31,400 every other month). A U.S. cost-utility model with authors from Apellis Pharmaceuticals, which included the costs and utility loss of informal caregiving, reported $77,735 per QALY gained over a lifetime horizon, and $55,806 per QALY gained for lesions at least 250 μm from the foveal center.

The Australian Pharmaceutical Benefits Advisory Committee (PBAC) assessed submissions for pegcetacoplan (November 2025) and avacincaptad pegol (March 2026). Each submission was a cost-utility analysis versus best supportive care with a 20-year time horizon; the pegcetacoplan model defined health states by ETDRS letter bands, and the avacincaptad pegol model by GA lesion size. For both products the PBAC stated that a price reduction would be required to achieve cost-effectiveness, and considered an ICER in the order of $55,000 to < $75,000 (pegcetacoplan) and $45,000 to < $55,000 (avacincaptad pegol) per QALY gained acceptable. For pegcetacoplan, the PBAC considered it reasonable to accept the financial estimates as the basis of a risk sharing arrangement. Should pegcetacoplan proceed to listing, the PBAC advised a cost-minimisation approach so that avacincaptad pegol was no more costly than pegcetacoplan. The NICE appraisal of pegcetacoplan was suspended after information the company provided in February 2025, which stated that it had not received MHRA marketing authorisation for the indication, and has since been discontinued.

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b); [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm); [Patel et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/37572871/); [Patel et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38777140/); [Cummings Joyner et al. (2023)](https://www.ispor.org/heor-resources/presentations-database/presentation/euro2023-3788/133629); [Pharmaceutical Benefits Advisory Committee pegcetacoplan (2025)](https://www.pbs.gov.au/industry/pbac/psd/2025/11/pegcetacoplan-psd-november-2025.pdf?variant=3); [Pharmaceutical Benefits Advisory Committee avacincaptad pegol (2026)](https://www.pbs.gov.au/industry/pbac/psd/2026/03/avacincaptad-pegol-psd-march-2026-a1151.pdf?variant=3); [National Institute for Health and Care Excellence pegcetacoplan appraisal (2026)](https://www.nice.org.uk/guidance/discontinued/gid-ta11351)

<a id="topic-4.1-2"></a>

### Manufacturer statement on payer assessment of cost-effectiveness

> “Furthermore, there can be no assurance that a product will be considered medically reasonable and necessary for a specific indication, that a product will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be established even if coverage is available or that the third-party payor’s reimbursement policies will not adversely affect the ability to sell a product profitably.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-4.1-3"></a>

### Pegcetacoplan cost-effectiveness analysis: U.S. Medicare costs and cost per QALY

> “Costs were based on 2022 Medicare reimbursement data. Specific outcomes were extrapolated from the DERBY and OAKS trials. Assumptions were made for the lifetime analysis based on a theoretical logistic growth model of the atrophy.”
> “The costs to treat GA in every month (EM) and every-other-month (EOM) treatment groups over the 2 years as reported were $70 000 and $34 600, respectively.”
> “The modeled lifetime costs were $350 000 (EM) and $172 000 (EOM), or $309 000/mm2 (EM) and $180 000 (EOM) /mm2.”
> “The costs/quality-adjusted life-year gained based on modeled visual loss with 95% atrophy were $706 000 (EM) and $397 000 (EOM).”
> “Treatment of GA with intravitreal pegcetacoplan EOM was more cost effective than EM.”

Source: [Patel et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/37572871/)

<a id="topic-4.1-4"></a>

### Avacincaptad pegol cost-effectiveness analysis: comparison with pegcetacoplan

> “Costs were based on 2022 Medicare reimbursement data for both facility (hospital-based) and nonfacility settings in Miami.”
> “The cost to treat GA with ACP in EM and EOM treatment groups over the 2 years as reported was $67 400 and $40 600, respectively.”
> “The (facility-based) costs per unit area of retinal pigment epithelium saved for patients with extrafoveal GA over the 2-year period were $119 000/mm2 (EM ACP) versus $54 000/mm2 (EM PEG) (P < 0.001), $57 100/mm2 (EOM ACP) versus $31 400/mm2 (EOM PEG) (P < 0.001), and $45 300/mm2 (hypothetical EOM from outset ACP).”
> “When assessing extrafoveal lesions, ACP was less cost effective than PEG for both EM and EOM treatment.”

Source: [Patel et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38777140/)

<a id="topic-4.1-5"></a>

### Pegcetacoplan de novo U.S. cost-utility model including informal caregiving

> “We developed a de novo cost-utility model for evaluating the treatment of GA and the impact of delaying vision loss.”
> “This is a health-state transition model with health states defined by best corrected visual acuity (BCVA) bands measured by Early Treatment for Diabetic Retinopathy Study (ETDRS) letters.”
> “When incorporating the costs and utility loss of informal caregiving for those with severe or total vision loss, the incremental cost per quality-adjusted life year (QALY) gained following treatment with pegcetacoplan is $77,735 assuming a lifetime model with costs and benefits discounted at 3.5%.”
> “Similarly, treating GA before the fovea is encroached, defined as GA with lesions at least 250 μm from the foveal center, carries an incremental cost of just $55,806 per QALY gained.”

Source: [Cummings Joyner et al. (2023)](https://www.ispor.org/heor-resources/presentations-database/presentation/euro2023-3788/133629)

<a id="topic-4.1-6"></a>

### Australian PBAC assessment of pegcetacoplan: model structure and ICER

> “Listing was requested on the basis of a cost-utility analysis (CUA) versus best supportive care (BSC).”
> “20 years (versus 24 month follow up in the DERBY and OAKS trials).”
> “Defined by number of ETDRS letters: ≥ 76, 75-66, 65-51, 50-36 and ≤ 35 letters and dead.”
> “The PBAC noted that multivariate analyses that incorporated each of these inputs increased the base case ICER from $45,000 to < $55,000 per QALY gained to $95,000 to < $115,000 per QALY gained.”
> “The PBAC considered the cost-effectiveness analysis would be more reliable with these alternative parameters and an incremental cost-effectiveness ratio (ICER) in the order of $55,000 to < $75,000 per QALY gained would be acceptable. A price reduction would be required to achieve cost-effectiveness based on the revised model.”

Source: [Pharmaceutical Benefits Advisory Committee pegcetacoplan (2025)](https://www.pbs.gov.au/industry/pbac/psd/2025/11/pegcetacoplan-psd-november-2025.pdf?variant=3)

<a id="topic-4.1-7"></a>

### Australian PBAC assessment of avacincaptad pegol: model structure, ICER, and cost-minimisation with pegcetacoplan

> “Listing was requested on the basis of a cost-utility analysis versus best supportive care (BSC).”
> “20 years (versus 18 months follow up in GATHER1)”
> “Defined by GA lesion size”
> “are proxies for disease severity and risk of vision loss but do not directly measure functional vision or visual acuity”
> “The ESC noted that this multivariate analysis increased the base case ICER from $55,000 to < $75,000 per QALY gained to $115,000 to < $135,000 per QALY gained.”
> “In this context the PBAC considered an ICER in the order of $45,000 to < $55,000 per QALY gained would be acceptable. The PBAC noted that a price reduction would be required to achieve cost effectiveness.”
> “Should pegcetacoplan proceed to PBS listing, the PBAC advised that a cost-minimisation approach (accounting for differences in administration costs) was appropriate to ensure that ACP was no more costly than pegcetacoplan.”

Source: [Pharmaceutical Benefits Advisory Committee avacincaptad pegol (2026)](https://www.pbs.gov.au/industry/pbac/psd/2026/03/avacincaptad-pegol-psd-march-2026-a1151.pdf?variant=3)

<a id="topic-4.1-8"></a>

### NICE appraisal of pegcetacoplan: suspension and discontinuation

> “Please note that following on from information provided to NICE by the company in February 2025, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.”
> “For information, the company have advised that they did not receive Marketing Authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication. Therefore, NICE has decided to suspend this appraisal from its current work programme.”

Source: [National Institute for Health and Care Excellence pegcetacoplan appraisal (2026)](https://www.nice.org.uk/guidance/discontinued/gid-ta11351)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
